The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $1,985,224 in first-year total cost, median $992,612.
Most frequent study sections
- Special Emphasis Panel[ZAA1 DD (44)]2
Most frequent institutions
- DICERNA PHARMACEUTICALS, INC.1
- MITOPOWER LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2021 | Novel therapy for alcoholic liver disease-associated hepatorenal syndrome1U44AA029833-01 | KOTTILIL, SHYAMASUNDARANSUBRAMANIAN, MANI | MITOPOWER LLC, CA | $985,224 | ZAA1 |
| 2018 | Development of an ALDH2-Targeting RNAi Therapeutic for Alcohol Use Disorders1U44AA027404-01 | BROWN, BOB D.DUDEK, HENRYK | DICERNA PHARMACEUTICALS, INC., MA | $1,000,000 | ZAA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.